Search details
1.
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9).
Breast Cancer Res Treat
; 190(1): 103-109, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-34453206
2.
Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study.
Breast J
; 25(2): 237-242, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30810258
3.
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Breast Cancer Res
; 19(1): 16, 2017 02 09.
Article
in English
| MEDLINE | ID: mdl-28183321
4.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Lancet Oncol
; 17(6): 791-800, 2016 Jun.
Article
in English
| MEDLINE | ID: mdl-27179402
5.
Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge.
Future Oncol
; 12(11): 1413-28, 2016 Jun.
Article
in English
| MEDLINE | ID: mdl-27007660
6.
Eribulin in "Field Practice": More from the Italian Experience.
Oncology
; 94 Suppl 1: 1-2, 2018.
Article
in English
| MEDLINE | ID: mdl-30036866
7.
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis.
Ther Adv Med Oncol
; 15: 17588359231165978, 2023.
Article
in English
| MEDLINE | ID: mdl-37063779
8.
Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients.
J Exp Clin Cancer Res
; 41(1): 78, 2022 Feb 25.
Article
in English
| MEDLINE | ID: mdl-35216615
9.
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial.
Mol Oncol
; 16(12): 2355-2366, 2022 06.
Article
in English
| MEDLINE | ID: mdl-34816585
10.
Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Cancers (Basel)
; 12(11)2020 Nov 10.
Article
in English
| MEDLINE | ID: mdl-33182575
11.
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer.
Cancers (Basel)
; 12(3)2020 Mar 06.
Article
in English
| MEDLINE | ID: mdl-32155941
12.
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.
Breast Care (Basel)
; 15(1): 30-37, 2020 Feb.
Article
in English
| MEDLINE | ID: mdl-32231495
13.
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives.
Crit Rev Oncol Hematol
; 139: 53-66, 2019 Jul.
Article
in English
| MEDLINE | ID: mdl-31112882
14.
Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy.
Cancers (Basel)
; 11(11)2019 Nov 08.
Article
in English
| MEDLINE | ID: mdl-31717320
15.
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.
PLoS One
; 14(8): e0220644, 2019.
Article
in English
| MEDLINE | ID: mdl-31390375
16.
Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?
Clin Breast Cancer
; 18(3): e363-e371, 2018 06.
Article
in English
| MEDLINE | ID: mdl-28958838
17.
Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer.
J Thorac Dis
; 8(6): E403-7, 2016 Jun.
Article
in English
| MEDLINE | ID: mdl-27293867
18.
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
Oncotarget
; 7(1): 255-65, 2016 Jan 05.
Article
in English
| MEDLINE | ID: mdl-26595802
19.
Current challenges in HER2-positive breast cancer.
Crit Rev Oncol Hematol
; 98: 211-21, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26638862
20.
Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available.
Tumori
; 99(6): 269e-72e, 2013.
Article
in English
| MEDLINE | ID: mdl-24503801